Navigation Links
MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
Date:1/25/2008

GERMANTOWN, Md., Jan. 25 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has entered into definitive purchase agreements with institutional investors for the private placement of 8,750,000 shares of its common stock at $2.40 per share. The transaction also includes five-year warrants to purchase 3,500,000 shares of common stock at an exercise price of $3.00 per share. The transaction is expected to raise $21 million in gross proceeds.

The transaction is expected to close within the next several days. Investors in the offering include existing shareholders and several additional new institutional investors.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM) served as exclusive placement agent for the transaction.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG(TM), its once-daily amoxicillin product, and for working capital and general corporate purposes.

"We believe the proceeds from this financing will provide sufficient capital to operate our business in 2008 and afford the Company greater flexibility and leverage as we seek to complete a strategic transaction over the coming months," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook. "We are very pleased to have received the support from our existing investors and several new investors in this financing."

The shares sold in the private placement and the shares issuable upon the exercise of the related warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission ("SEC") or through an applicable exemption from SEC registration requirements. The shares and warrants were offered and sold only to institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the common stock issued in the private placement and issuable upon the exercise of the warrants.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of the Company.

About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) increase Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
2. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
3. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
4. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
5. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
6. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
7. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
8. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
9. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
10. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
11. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... City, Utah (PRWEB) , ... February 11, 2016 ... ... wireless microFET medical dynamometers and ergoFET force gauges used in physical therapy, occupational ... Rehab Strength Indicator sensor for resistance cord exercise and therapy, introduces its new ...
(Date:2/11/2016)... ... ... The book, “Computers Should Just Work!”, provides a basic, non-techie education on ... before signing a contract and how to spot an incompetent or dishonest IT person ... e-mail and technology, it’s more important than ever to make sure the company you ...
(Date:2/10/2016)... WASHINGTON (PRWEB) , ... February 10, 2016 , ... ... to expand the ability of Medicare Advantage organizations to deliver medical services via ... , “ATA has been advocating for such language for many years. ...
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare ... conditions, announced today that the Company will present its ... on Tuesday, February 16, 2016, at 4:30 p.m. ET.  ... overview of its business and growth strategy, as well ... 31, 2015. --> ...
(Date:2/11/2016)... , Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development of a once-daily, oral therapy for ... Chief Medical Officer, Dr. Maya Halpern , has notified ... Chief Medical Officer and from its Board of Directors ... reaching retirement age. Allen Baharaff . Mr. ...
(Date:2/11/2016)... , February 11, 2016 ... Autoclave Market Report 2016 research report provides information ... regions, development status with crucial statistical data and ... http://www.deepresearchreports.com/142870.html . --> Complete report ... 19 companies and supported with 296 tables and ...
Breaking Medicine Technology: